Thyroid cancer is the most common endocrine malignant tumor in the world, and its incidence is increasing. Although the mortality rate of thyroid cancer is low, its persistence/recurrence rate is high. In addition, some patients with thyroid cancer fail to respond to radiation. Therefore, it is urgent need to develop a novel treatment for thyroid cancer. Parthenolide (PTL), a traditional Chinese medicine Tanacetum parthenium extract, has shown encouraging effects in anti-tumor, anti-inflammatory and anti-malaria. However, it is unclear whether PTL has an anti-thyroid cancer effect and its possible mechanism of action. In the recent years, metabonomics has been widely used in tumors research to explore the pharmacological mechanism of drugs, but few studies used metabonomics to investigate the pharmacological effects of PTL in thyroid tumors. In order to comprehensively reveal the mechanism and effects of PTL on anti-thyroid tumors, metabonomics combined cell biological research methods were conducted. The results showed that PTL promote apoptosis of thyroid cancer cells (TPC-1) in a concentration-dependent manner. The metabolic differences between the PTL group and the control group were compared by metabonomics, and 31 potential metabolites were identified. These metabolites were mainly involved in the tricarboxylic acid cycle, amino acid metabolism, choline metabolism and lipid metabolism. These results implied that PTL may inhibit the proliferation and development of thyroid carcinoma by accelerating oxidation emergency response, inhibiting adenosine triphosphate (ATP) synthesis and metabolic imbalance. The results of this study revealed that PTL can be an effective and potential drug for the treatment of thyroid cancer.
Keywords: Apoptosis; Metabolic imbalance; Metabonomics; Parthenolide; Thyroid cancer.
Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.